Driving the future of non-surgical endometriosis diagnosis: Hera Biotech acquires Scailyte’s endometriosis diagnostic assets

Basel, Switzerland, January 2024 – By acquiring Scailyte’s endometriosis diagnostic assets, US-based Hera Biotech makes a major advancement in improving diagnosis accuracy and patient care. This consolidation is expected to speed up the creation of clinical tools for diagnosing and stratifying endometriosis patients and facilitate the development of targeted therapies.

2023 Scailyte Hera PressRelease


HEMEX is a CRO providing clinical services to European biotech and medtech companies, assisting them throughout the clinical development process to ensure that products reach the market swiftly. Located in the Basel region, a major life sciences hub, and with offices in Germany, Benelux, and the United States, we are well positioned to serve small and medium enterprises (SMEs) with multinational clinical projects. The comprehensive package of services we provide includes clinical operations, quality management, regulatory guidance, grant writing services, and fundraising options. At HEMEX, we guarantee fast and clear communication, local accessibility, and transparency to meet the objectives of our clients. For more information, visit https://hemex.ch/